These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8945704)

  • 21. Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results.
    De Maria A; Tundo P; Romano A; Grima P
    Adv Exp Med Biol; 1995; 371B():1599-600. PubMed ID: 7502864
    [No Abstract]   [Full Text] [Related]  

  • 22. Herpes simplex virus vaccines.
    Wise TG; Pavan PR; Ennis FA
    J Infect Dis; 1977 Nov; 136(5):706-11. PubMed ID: 199677
    [No Abstract]   [Full Text] [Related]  

  • 23. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An outbreak of herpes simplex virus type I gingivostomatitis in a dental hygiene practice.
    Manzella JP; McConville JH; Valenti W; Menegus MA; Swierkosz EM; Arens M
    JAMA; 1984 Oct; 252(15):2019-22. PubMed ID: 6090717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8
    Srivastava R; Khan AA; Chilukuri S; Syed SA; Tran TT; Furness J; Bahraoui E; BenMohamed L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The quest for a herpes simplex virus vaccine: background and recent developments.
    Hall MJ; Katrak K
    Vaccine; 1986 Sep; 4(3):138-50. PubMed ID: 3020819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular involvement in an outbreak of herpes gladiatorum.
    Holland EJ; Mahanti RL; Belongia EA; Mizener MW; Goodman JL; Andres CW; Osterholm MT
    Am J Ophthalmol; 1992 Dec; 114(6):680-4. PubMed ID: 1334374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice.
    Walker J; Laycock KA; Pepose JS; Leib DA
    Vaccine; 1998 Jan; 16(1):6-8. PubMed ID: 9607002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Herpes simplex virus, type II: microbiology and clinical experiences with attenuated vaccine].
    Nasemann T; Schaeg G
    Hautarzt; 1973 Apr; 24(4):133-9. PubMed ID: 4351533
    [No Abstract]   [Full Text] [Related]  

  • 33. Live vaccinia virus recombinants expressing herpes simplex virus genes.
    Rooney JF; Wohlenberg CR; Moss B; Notkins AL
    Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex virus vaccine in recurrent herpetic ocular infection.
    Pivetti-Pezzi P; Accorinti M; Colabelli-Gisoldi RA; Pirraglia MP; Sirianni MC
    Cornea; 1999 Jan; 18(1):47-51. PubMed ID: 9894936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grappling with herpes: herpes gladiatorum.
    Becker TM; Kodsi R; Bailey P; Lee F; Levandowski R; Nahmias AJ
    Am J Sports Med; 1988; 16(6):665-9. PubMed ID: 2853577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.
    Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L
    Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Herpes simplex virus vaccines: perspectives].
    Deback C; Huraux JM
    Rev Med Interne; 2007 Jan; 28(1):16-21. PubMed ID: 17095125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus.
    Irie H; Shimeld C; Williams N; Hill T
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1357-62. PubMed ID: 8393076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.